Welcome to our dedicated page for Tandem Diabetes news (Ticker: TNDM), a resource for investors and traders seeking the latest updates and insights on Tandem Diabetes stock.
Tandem Diabetes Care (TNDM) delivers innovative insulin management solutions through advanced pump technology and connected diabetes care platforms. This news hub provides investors and healthcare professionals with timely updates on corporate developments, product milestones, and regulatory progress.
Access official press releases covering quarterly financial results, new product clearances, and strategic partnerships alongside analysis of market trends impacting diabetes care technology. Our curated collection ensures you stay informed about pump software updates, clinical trial outcomes, and international expansion efforts.
Key updates include FDA submissions, insulin delivery system enhancements, and operational developments across global markets. Bookmark this page for direct access to Tandem Diabetes' latest announcements, including pump compatibility improvements and user experience initiatives that shape modern diabetes management.
Tandem Diabetes Care reported strong Q1 2025 financial results, with worldwide sales growing 22% to $234.4 million. The company achieved record first-quarter performance, with U.S. pump sales increasing 19% and significant international growth.
Key highlights include:
- Worldwide pump shipments exceeded 28,000 units
- International sales reached $83.8 million
- U.S. sales showed robust growth with over 17,000 pump shipments
- 5-point improvement in adjusted EBITDA margin
- 30% of U.S. lives now covered through pharmacy benefits for Tandem Mobi
The company reaffirmed its 2025 guidance, projecting full-year sales between $997 million to $1.007 billion. Despite posting a GAAP net loss of $130.6 million, Tandem's non-GAAP metrics showed operational improvements, with gross margin reaching 51% compared to 49% in the previous year.
Tandem Diabetes Care (TNDM), a leading insulin delivery and diabetes technology company, has scheduled its first quarter 2025 financial results announcement for April 30, 2025, after market close.
The company will host a conference call and simultaneous webcast at 4:30 PM Eastern Time (1:30 PM Pacific Time) to discuss Q1 2025 financial and operating results. Investors can access the live webcast through Tandem's Investor Center website, and a recording will be available for 30 days afterward.
Tandem Diabetes Care (TNDM) announced positive results from its pivotal trial of Control-IQ+ automated insulin delivery technology for type 2 diabetes, published in The New England Journal of Medicine. The 13-week study showed significant improvements in glycemic control across a diverse population of 319 participants.
Key findings include:
- A1C reduction of 0.9% in Control-IQ+ group vs 0.3% in control group
- 2.3% A1C reduction in participants with baseline A1C ≥9%
- Time in range improved by 16%, adding 3.8 more hours/day in target range
- Insulin use decreased by 8 units/day in Control-IQ+ group
The study demonstrated effectiveness across diverse demographics, with 39% of participants from minority backgrounds. The technology proved safe with no new safety concerns, and received high usability scores regardless of participants' bolusing strategy.
Tandem Diabetes Care (NASDAQ: TNDM) has launched Control-IQ+ technology in the United States, an enhanced automated insulin delivery (AID) system now available for people with type 1 diabetes aged 2 years and older and adults with type 2 diabetes.
The new generation algorithm, compatible with both t:slim X2 insulin pump and Tandem Mobi System, offers expanded features including:
- Wider weight (20-440 lbs) and total daily insulin (5-200 units) parameters
- Enhanced extended bolus up to 8 hours with active Control-IQ+
- New Temp Basal Rate adjustments during active Control-IQ+
The technology is now shipping in pre-loaded pumps to new customers, while eligible in-warranty Tandem customers can access the update via free remote software update. The system maintains the company's unique AutoBolus™ feature, adjusting insulin every 5 minutes based on predicted glucose values.
Tandem Diabetes Care (TNDM) reported strong financial results for Q4 and full year 2024. Q4 worldwide GAAP sales grew 44% to $282.6M, with non-GAAP sales up 21% to $252.4M. Pump shipments increased by over 25% worldwide.
For full year 2024, worldwide GAAP sales rose 26% to $940.2M. The company achieved positive free cash flow and increased Tandem Mobi pump shipments throughout the year. Strategic highlights include FDA clearance for Control-IQ+ for type 2 diabetes and a multi-year collaboration with University of Virginia for closed-loop insulin delivery systems.
Looking ahead to 2025, TNDM projects full-year sales of $997M-$1.007B, with U.S. sales of $725M-$730M and international sales of $272M-$277M. Q1 2025 sales are estimated at $219M-$224M. The company expects a gross margin of approximately 54% for 2025.
Tandem Diabetes Care (Nasdaq: TNDM) has received FDA clearance for its Control-IQ+ automated insulin delivery technology for people with type 2 diabetes aged 18 and older. This next-generation algorithm, already approved for type 1 diabetes, includes enhancements to accommodate expanded weight and total daily insulin ranges.
The technology will be available for U.S. customers in March 2025. Control-IQ+ powers both the t:slim X2 and Tandem Mobi insulin delivery systems, which have shown significant clinical benefits in type 1 diabetes patients, including improved time in range and better sleep according to studies published in the New England Journal of Medicine.
The expanded indication is based on a pivotal trial involving over 300 people with type 2 diabetes, comparing the t:slim X2 pump with Control-IQ+ technology against multiple daily injections. Full study results will be presented at the International Conference on Advanced Technologies & Treatments for Diabetes in Amsterdam in March 2025.
Tandem Diabetes Care (TNDM), a leading insulin delivery and diabetes technology company, has announced its participation in four major healthcare investor conferences in March 2025:
• TD Cowen 45th Annual Health Care Conference - March 4, 2025, 1:50pm ET
• Barclays 27th Annual Global Healthcare Conference - March 11, 2025, 1:30pm ET
• Leerink Partners 2025 Global Healthcare Conference - March 12, 2025, 9:20am ET
• Oppenheimer 35th Annual Healthcare MedTech & Services Conference - March 20, 2025, 12:40pm ET
Management will present company updates at each conference. All presentations will be available via live webcast and archived for 30 days on Tandem's Investor Center website under the 'Events & Presentations' section.
Tandem Diabetes Care (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, has announced it will release its fourth quarter and full year 2024 financial results after market close on Wednesday, February 26, 2025.
The company will host a conference call and simultaneous webcast at 4:30 PM Eastern Time (1:30 PM Pacific Time) on the same day to discuss the financial and operating results. Investors can access the live webcast through Tandem's Investor Center website. A recording of the webcast will be available for 30 days following the event in the "Events & Presentations" section.
Tandem Diabetes Care (TNDM) has announced a multi-year collaboration agreement with the University of Virginia Center for Diabetes Technology (UVA) to advance research and development of fully automated closed-loop insulin delivery systems. The partnership builds on their previous successful collaboration in the International Diabetes Closed Loop trials.
The collaboration combines UVA's expertise in technology-based interventions and automated insulin delivery (AID) algorithms with Tandem's market leadership in insulin delivery devices, algorithm implementation, and data management. The research will involve scientists, clinicians, and experts from both institutions, potentially leading to clinical research for Tandem's next-generation AID systems.
As part of the agreement, Tandem will provide research funding, technology, and supplies to UVA for diabetes-centered research and potential clinical studies.
Tandem Diabetes Care and Dexcom announced that Health Canada has authorized the sale of the t:slim X2™ insulin pump with full compatibility for both Dexcom G6 and G7 Continuous Glucose Monitoring (CGM) Systems. This makes the t:slim X2 the first insulin pump in Canada integrated with both CGMs. The t:slim X2, which features Control-IQ technology, is highly rated and now offers Canadian users more options for diabetes management.
The integration launched in the U.S. in December 2023, and now Canadian users can benefit from the faster 30-minute sensor warm-up time of the Dexcom G7 and the ability to view glucose levels on an Apple smartwatch. Tandem will provide the new compatibility feature free of charge via a remote software update to in-warranty users and will begin shipping updated pumps in early January 2025. For more information, users can visit tandemdiabetes.ca or dexcom.com.
FAQ
What is the current stock price of Tandem Diabetes (TNDM)?
What is the market cap of Tandem Diabetes (TNDM)?
